ROLE OF EFFECTIVE PROJECT MANAGEMENT IN REDUCING DRUG DEVELOPMENT COST by Zaidi, Faisal BA et al.
Vol 10, Issue 3, 2017
Online - 2455-3891 
Print - 0974-2441
ROLE OF EFFECTIVE PROJECT MANAGEMENT IN REDUCING DRUG DEVELOPMENT COST
FAISAL BA ZAIDI1*, SALMA AHMED1, MUNISH MAKKAD2
1Department of  Business Administration, Faculty of Management Studies and Research, Aligarh Muslim University, Aligarh, 
Uttar Pradesh, India. 2Department of Management, Birla Institute of Technology, Noida, Uttar Pradesh, India. 
Email: faisalbazaidi@gmail.com
Received: 23 November 2016, Revised and Accepted: 30 November 2016
ABSTRACT
Pharmaceuticals are passing through the difficult phase due to increasing numbers of patents expiry along with increasing cost of drug development. 
Protocol design, regulatory cycle time, site selection, patient enrollment  and monitoring are some of the cost contributing elements for late phase 
clinical trials. This paper applies the principles of project management and suggests means to reduce the cost of late phase drug development. It also 
throws light on the critical role that a project manager can play in overall  drug development process.
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INTRODUCTION
Drug development is a complicated process and extremely challenging 
to execute. It takes lots of efforts and expertise to develop one drug 
and it is estimated that one drug reaches to the market after around 
1000 failed discoveries [1]. The cost of a typical drug development is 
around 1.2 billion USD [2] and it is increasing each year while more 
number of failures at later stage makes it costlier. Data suggest that 
only one out of 25 preclinical molecules would reach to the approval 
status [3] while the success rate of Phase I to approval is suggested 
as 12% [4]. The success of clinical trial also varies with phases and it 
is reported as 67%, 41% and 55% for Phase I, Phase II and Phase III 
trials, respectively [1]. Two separate studies from year 2010 to year 
2011 suggest the clinical trial success probabilities as 19% and 9% [1] 
separately.
Pharmaceutical organizations are passing through difficult phase due 
to increasing numbers of patent expiry of their marketed products 
which in turn impact their revenue. It is estimated that sales of major 
pharmaceutical companies may have been reduced to 44% because of 
patent expiry between years 2009 and 2014 with brands worth USD 
128 billion losing the patent in the same time period [2].
On the other hand, it has become extremely difficult to launch new 
drug due to increasing development cost. There is no doubt that late 
phase development, i.e. Phase II and Phase III are the costliest phases of 
drug development and constitute around 90% of the total development 
cost [2]. In the absence of blockbuster and first in class molecule, it is 
becoming more and more demanding for pharmaceutical companies 
to get their investment back and one report estimated that only one 
out of five drugs will be able to provide the revenue equivalent to or 
more than its investment [2]. It has become a grim assignment for 
pharmaceutical companies to persuade the investors and partners to 
invest in late phase development in the absence of not so promising 
result from earlier phases. It is very challenging to forecast the budget 
of a clinical trial, and only 14% financial planners will be sure of their 
budget [5].
Industry experts estimated that late phase drug development is the 
costliest phase of drug development. Costly late phase development can 
be considered as one of the reasons that more than 40% of the marketed 
products during 2003-2013 were acquired [6] as pharmaceutical 
companies would prefer to invest in the molecule which is in later phase 
to avoid major loses. If one looks closely at the activities performed in 
the late phase drug development and would know that these are majorly 
project management activities. These activities would include protocol 
design, vendor identification and selection, site identification and 
selection, regulatory submission and approval, site initiation, patient’s 
enrollment; site monitoring, data management, audit/inspection and 
site close out, etc. Fig. 1 illustrates that each of these activity is part 
of a project or a complete project in itself depending on the size of the 
trial, e.g., for a large Phase III trial, site selection can be a project in 
itself while in case of relatively smaller Phase II trial, it can be one of 
the tasks of overall project. The focus below is on those activities which 
are major cause of cost increase and can be managed through effective 
project management.
PROTOCOL DESIGN
Clinical trial protocol increasingly getting complicated day by day due 
to various reasons. Increasing knowledge of science, i.e., availability 
of disease history, demography, etiology, molecular knowledge of the 
drug, and biomarker studies, are some of the reasons for increasing 
complexities of the clinical trial. Increasing size of the trials is another 
major factor for the complexities of the trial as each geographical region 
will have its own concern and the data coming from each region would 
require to be addressed. Some countries do not allow placebo control 
studies and it is one of the important considerations during protocol 
designing while planning the trial which involves such regions. On the 
other hand, protocol complexities would also impact various other 
associated activities such as patient enrollment, drug shipment, and 
monitoring which certainly would influence the cost of clinical trial. 
A survey conducted in year 2011 with 79 organizations involved in 
conducting clinical trial revealed that trial design was the first factor in 
determining the frequency of the monitoring in the study [7]. Another 
report suggests that total procedures per trial protocol have increased 
from 105 in year 2000-2003 to 166 in year 2008-2011 [8], while 
clinical trial treatment period (median days) increased from 140 to 
175 [4].
It is noticed that protocol writing team work independently and inputs 
are sought from other functions only in the later phase of protocol 
development. It is important that collaboration in the beginning itself is 
very significant to discuss the upcoming challenges of proposed protocol 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16186
Review Article
54
Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 53-56
 Zaidi et al. 
and inputs from regulatory, clinical operations, data management, 
manufacturing, and various other functions. It would be a help for 
medical writer to understand the anticipated challenges and get the 
solutions from other team members, for instance, the manufacturing 
unit may not be equipped to provide the sufficient investigation product 
as per anticipated high patient enrollment rate, clinical operation may 
not be having sufficient resources to monitor the data generated at sites, 
etc. It is interesting to note here that 43% of the protocol amendments 
happened even before first patient enrollment [1]. It is understandable 
that it is difficult to simplify a complex trial protocol for various 
scientific reasons; however, the associated cost can certainly be reduced 
by improving the planning at protocol development. Complexity of 
the protocol may lead to increase in clinical trial duration by 64% [9]. 
There is software available to help in deciding the number of patients, 
regions, etc. which can help in cost saving by better planning [10] as 
approximately 45% of the pharmaceutical financial professionals would 
fail to forecast the budget accurately [10].
REGULATORY SUBMISSION AND APPROVAL
One of the most important milestones for conducting clinical trial 
is to get a go ahead from regularity authorities. It requires lots of 
expertise to avoid any delay and queries from regulatory authorities 
as delay in getting regularity approval may impact the overall conduct 
and planning of a clinical trial, e.g., delay in getting approval for an 
asthmatic or allergic rhinitis trial may postpone the overall enrollment 
of the patients in the trial. It is interesting to note that a single day delay 
of market authorization approval can lead to a potential sales loss of 
USD 8 million [11] It is very difficult to forecast the regulatory approval 
time for the multicenter trial because of varied timeline and dynamic 
structure of different regulatory authorities. However, planning may 
help in saving some time like getting feedback from the key opinion 
leaders and clinical practitioners during the protocol designing would 
surely help in avoiding queries from regulatory authorities on conduct 
and design of the study. There are some regulatory authorities which 
allow to have a meeting to discuss the design and such opportunities 
could be utilized to avoid queries later. According to a study conducted 
on 302 first new molecular entities drug applications first submitted 
to the Food and Drug Administration (FDA) for the period between 
years 2000 and years 2012, it was found that 71 applications failed 
to get approval in the first submission and required at least second 
submission which added a medial delay of 435 days [12]. Time is 
precious when it comes to drug development as even single day delay 
may cost a lot to the pharmaceutical companies. There is an increase 
of 11% reported in the regulatory cycle time between years 2000 and 
years 2005 though there is decrease in US FDA regulatory approval 
time reported in recent past [1]. Sometime it also happen that outcome 
of a Phase II trial would lead to next phase. According to a study which 
covered over 3600 protocol, over one-third of the protocol amendments 
would have been avoided by better planning in the beginning. Each 
protocol amendment directly impacts the cost as it may be associated 
with other process and procedure, i.e., principle investigator’s fee and 
site fee, clinical procedure, new vendors, additional drug and other 
supply at sites, change in informed consent and other patient material 
as it would also require the ethics committee approval and around 
69% of the protocol would have at least one amendment [8]. The same 
study further added that the cost of each protocol amendment stands as 
$453,932 [1] which is considerable while it should be noted that 37% 
of protocol amendments can be avoided thus leading to cost saving [8].
SITE SELECTION AND ENROLLMENT
Investigator site selection is one of the most challenging tasks in late 
phase clinical trials as it is increasingly becoming difficult to identify 
Fig. 1: Typical activities of clinical trial and phases of project management
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newer sites for the trial considering that number of experienced 
principal investigators is reducing at a rate of 6% after 2001 [13] 
which is compelling the pharmaceutical companies to go for first 
time investigator. On the other hand, a center watch report suggests 
an alarming dropout rate of 50% of the first time investigator during 
the period of years 2001-2004 [13]. Another study for the period 
of year 2000 and 2007 suggests the reduction of 10% in the new 
investigator [14]. There are various reasons for the reduction in number 
of sites or principle investigators which primarily include the complexity 
of the trial and increased regulatory vigilance that demands a close 
oversight, proper attention, accurate documentation and time allocation 
by the principle investigator and other site staff. It is well understood 
by the industry that compensation to the principle investigator should 
be well balanced and they try to keep it as low as possible which in 
turn results in lack of interest at site level. Site selection contributes to 
the overall clinical trial cost and USD 20,000-30,000 is the approximate 
cost of initiating a site while it would cost around USD 1500 to maintain 
the clinical site [14] which would come enormous for a global clinical 
trial. This shows that how much cost it would add to the clinical trial if 
a wrong site is selected. Fig. 2 shows some elements to note during site 
selections which play a key role to get the best sites selected. Selection 
of the right site is very important as around 50% of the site do not meet 
enrollment target and enroll only one patient or even fail to recruit 
one patient [14]. A study suggests that site retention costs constitute 
around 9% to 16% of a clinical trial across all phases [1].
Another significant factor which plays a major role in the late phase 
clinical trial is subject enrollment as it is projected that 80% trials do 
not complete the enrollment within timelines [5], and this delay would 
cost approximately USD 35,000/day [5]. Site performance is also largely 
dependent on the therapeutic area along with other factors. A data 
collection study conducted during the year 2006-2010 by Covance 
suggests that highest non-performing sites come from oncology (60%) 
followed by hematology (57%) while dermatology stands best with just 
37% nonperforming sites [11]. Other factors playing a major role in sites 
performance are protocol design, placebo arm, trial budget, etc. Subject 
enrollment is responsible for around 45% delays in trial completion [14] 
and around 30% of phase III clinical trial do not complete on time 
while this percentage is around 42% and 31% for Phase I and Phase II, 
respectively [11]. According to a study conducted by University of North 
Carolina in year 2006, around 15-20% sites would fail to enroll while 
30% of the site would enroll below than estimates [4].
MONITORING
Monitoring is another cost contributing activity for late phase clinical 
trial as industry expert estimated around 15-30% of the cost linked to 
monitoring [3]. There are various cost which are directly associated 
with the monitoring, e.g., a protocol amendment would lead to change 
in the safety or efficacy assessment and informed consent changes 
which mean additional time spent by the monitor at sites, additional 
nights spent in hotel and additional flight taken by the monitor. About 
100% source data verification followed by most of the pharmaceutical 
organizations is also considered as an additional burden by the industry 
experts as it is not a regulatory requirement. Risk-based monitoring 
approach is adopted as a replacement of traditional monitoring by 
some pharmaceutical companies. One of the reports published by 
Cutting Edge Information suggests that risk-based monitoring can 
save significant monitoring cost. The report suggests saving of 21% 
for Phase III clinical trial and 14% for Phase II clinical trial conducted 
by contract research organizations (CROs) while it is around 32% 
and 11% for Phase III and Phase II trials, respectively, in case of trials 
conducted by the pharmaceutical organization [15]. Cost saving by risk-
based monitoring would also depend on therapeutic area, phase, size, 
protocol complexity of the trial and each study should be evaluated 
thoroughly before implementing risk-based monitoring. A year 2010 
study suggest a cost reduction of 23% by reducing the source data 
verification to 50% and reducing the frequency of monitoring visit 
from 6 weeks to 10 weeks in an oncology phase 3 study [1]. One of 
the leading CRO Quintiles suggests a cost reduction of 25% through 
risk-based monitoring [16]. Selection and implementation of risk base 
monitoring data points is very crucial for late phase trials considering 
that there is 83% likelihood of receiving market authorization approval 
from US FDA after completion of Phase III trial [1].
Various other ways of reducing monitoring cost such as preplanned 
travel booking, corporate tie ups with hotels, assignment of regional 
monitors to save travel cost would also play a major role in saving 
monitoring cost.
Fig. 2: Elements for site selection
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Other factors there are various other factors which also influence the cost of 
clinical trial. There is ethics committee cost which would increase with the 
cost of protocol and informed consent form amendments, administrative 
staff costs constitute around 11%-29% and can be reduced by effective 
resource management. Central laboratory supplements significant costs 
(4-12%) [1] and number of additional procedure can increase the cost of 
a clinical trial by 65% [5]. Local labs are cheaper compared to central labs 
and using local lab may reduce the cost significantly.
It is important to note that shifting clinical trial sites to India, China, 
and other emerging countries may reduce the cost around 60% [17] 
despite the fact that some of the related cost would increase, e.g., the 
cost of translation cost, especially in those regions where English 
is not the primary or official language and translation is done for 
various regulatory requirements. However, it is observed that various 
documents are unnecessarily translated as a precautionary measure 
with no use and avoiding them could help in saving some cost.
Increasing complexities and globalization of clinical trial has also lead 
to shipment challenges. It is easier to ship the investigational drug 
to one country or region as compared to the shipment to multiple 
countries and regions as it would require temperature control, 
regulatory restrictions, import license to name a few. Although data 
management generally does not add to the avoidable cost; however, 
timely integration of various software and data platform can also play a 
big role in delay and cost saving. Study budget negation and finalization 
also cause delay for 49% of the study [18].
PROJECT MANAGER - A KEY STAKEHOLDER
A clinical trial project consists of typical phases of a project, i.e. initiating 
planning, executing, monitoring and controlling, and analysis and 
reporting. It requires lots of planning and effective execution to 
complete the clinical trial successfully. A typical drug development 
project would have a project leader who works as guiding force for 
the several clinical trials in various phases. Project leader would have 
many project managers, each responsible for conduct of a clinical 
trial, reporting to him directly for the progress of the clinical trials. 
Project managers are well aware of the progress of clinical trial and 
any change in the timelines, cost and resourcing due to several factors. 
Project leader can decide the next stage of development based on the 
information received from other project managers. There could be 
cases of holding the further development for another clinical trial due 
to safety issues reported in one of the trial. This could result in huge cost 
saving. Therefore, one of the most important role of a project leader is 
to keep the communication live between various project managers and 
seek their inputs based on the progress of the trial.
Further project managers need to focus on each stage of clinical trial 
and manage the resource as required while getting the best and timely 
outcome of a clinical trial. They are expected to take the decision about 
site related cost, location of region and sites, keep an eye of the progress 
of clinical trial and safety inputs and the trend for protocol deviation. 
Other significant tasks of a project manager are to a track time and cost 
of the trial and report it project leader in a timely manner. An efficient 
project manager is one who keeps the ball rolling and works as an 
integrator for various member of the team.
CONCLUSION
Increasing drug development cost has become a challenge for 
pharmaceutical industry and is impacting the launch of new drug in the 
market. There are 5000 drugs in the development phase worldwide [4] 
across various therapeutic areas which reflect the money at risk as 
only around 10% of the drug candidate entering clinical trial would 
pass [19]. This can certainly be reduced by improving the processes 
and adapting effective project management practices in place. The 
money saved can be utilized by the pharmaceutical companies for 
future development. Reduction in cost of drug development will also 
encourage other mid and small size pharmaceuticals to come forward 
and invest in drug development.
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